Melanocortin receptor agonist peptides — melanotan I, melanotan II, and bremelanotide — work through central brain pathways to enhance sexual arousal and function in both men and women, representing a fundamentally different approach from drugs like Viagra.
3 peptide drugs reviewedMelanotan I, melanotan II, and bremelanotide — melanocortin receptor agonist peptides developed for male and female sexual dysfunction through central brain pathways
What the researchers found
Clinical development of three melanocortin receptor (MCR) agonist peptides has advanced understanding of how the melanocortin pathway regulates sexual function. Melanotan I, melanotan II, and bremelanotide have been studied for treating erectile dysfunction in males and sexual arousal and orgasmic disorders in females.
Unlike phosphodiesterase-5 inhibitors (e.g., sildenafil/Viagra) that act peripherally on nitric oxide/cyclic GMP signaling in genital smooth muscle, MCR agonists target central nervous system pathways involved in mediating arousal and orgasm. The available data support the role of melanocortin pathway activation in regulating both male and female sexual functions, warranting further clinical investigation.
Why it matters
Sexual dysfunction affects millions of people, and current treatments have significant limitations. PDE5 inhibitors work for many men with ED but don't address desire or arousal, and no comparable options existed for women until recently. Melanocortin peptide agonists represent a fundamentally different therapeutic mechanism — targeting brain circuits that control sexual motivation and arousal rather than just genital blood flow. Bremelanotide was eventually FDA-approved in 2019 for female hypoactive sexual desire disorder, validating this peptide-based approach.
How the study worked
Narrative review summarizing basic research and clinical study results for melanocortin receptor agonist peptides (melanotan I, melanotan II, bremelanotide) in the treatment of male erectile dysfunction and female sexual arousal and orgasmic disorders.
What this study cannot tell us
The review was published in 2014 and does not include the final clinical trial results that led to bremelanotide's FDA approval in 2019. Melanotan I and II were associated with side effects including nausea and skin darkening (due to melanocyte stimulation) that complicated their clinical development. The central mechanism of action raises questions about potential CNS side effects with long-term use. The exact melanocortin receptor subtypes mediating sexual effects were not fully characterized at the time of this review.
How to read the evidence
This is a narrative review summarizing basic research and clinical study results. It provides a useful overview of the field at a specific time point (2014) but does not present new data or conduct a systematic analysis.
When this study was published
Published in 2014, this review predates the FDA approval of bremelanotide (Vyleesi) in 2019 for female hypoactive sexual desire disorder. The review's conclusions were subsequently validated by the clinical development and approval process.
The bigger picture
This review captures an important chapter in peptide drug development: the translation of melanocortin biology into sexual medicine. The melanocortin system was originally studied for its role in pigmentation and appetite, but its involvement in sexual function opened an entirely new therapeutic application. Bremelanotide's eventual FDA approval (2019, as Vyleesi) validated this approach and remains one of the few centrally-acting sexual dysfunction treatments available. The broader melanocortin peptide field continues to expand into obesity, inflammatory disorders, and other conditions.
Questions still open
- Can melanocortin receptor agonists be optimized to selectively enhance sexual function without causing skin pigmentation changes?
- Does long-term use of centrally-acting melanocortin peptides for sexual dysfunction carry risks for mood, appetite, or other brain functions?
- Could melanocortin agonists be combined with peripheral-acting drugs like PDE5 inhibitors for patients with both desire and arousal deficits?
Common questions
How are melanocortin peptides different from Viagra for sexual dysfunction?
Is bremelanotide (Vyleesi) available now?
Read the original research
Melanocortin receptor agonists in the treatment of male and female sexual dysfunctions: results from basic research and clinical studies.
Expert opinion on investigational drugs, 23(11), 1477-83
Citation
Ückert, Stefan; Bannowsky, Andreas; Albrecht, Knut; Kuczyk, Markus A. (2014). Melanocortin receptor agonists in the treatment of male and female sexual dysfunctions: results from basic research and clinical studies.. Expert opinion on investigational drugs, 23(11), 1477-83. https://doi.org/10.1517/13543784.2014.934805